冠状动脉慢血流现象的研究进展

doi:10.3969/j.issn.2095-378X.2019.01.013

外科研究与新技术 ›› 2019, Vol. 8 ›› Issue (1): 44-48.doi: 10.3969/j.issn.2095-378X.2019.01.013

冠状动脉慢血流现象的研究进展

曹梦珠¹(综述), 乔增勇²(审校)

1.安徽理工大学医学院心内科,淮南 232000;
2.上海交通大学附属第六人民医院南院心内科,上海 201400

收稿日期:2018-12-26 出版日期:2019-03-28 发布日期:2019-12-09
通讯作者: 乔增勇,电子信箱:qiaozy666@sina.com
作者简介:曹梦珠(1992—),女,硕士研究生在读
基金资助:
上海市奉贤区科学技术委员会重大课题(20170703)

Advances in coronary slow flow

CAO Mengzhu¹, QIAO Zengyong²

1.Department of Cardiovascular Medicine, Medical College, Anhui University of Science and Technology, Huainan 232000, China;
2.Department of Cardiovascular Medicine, The South Branch of the Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai 201400, China

Received:2018-12-26 Online:2019-03-28 Published:2019-12-09

摘要/Abstract

摘要： 冠状动脉慢血流(coronary slow flow,CSF)实质上是指正常或接近正常的心外膜冠状动脉(狭窄<40％),在冠状动脉造影期间使用造影剂,其远端血管浑浊延迟显现的现象。CSF与急性心肌梗死、室性心动过速、心室颤动甚至心源性猝死有关,超过80％的患者会出现反复的胸痛,导致生活质量严重下降。本文主要介绍CSF可能的发病机制、临床特征、预测因素以及治疗研究进展。

关键词: 冠状动脉慢血流, 冠状动脉造影, 胸痛

Abstract: Coronary slow flow (CSF) refers to a phenomenon of delayed distal vessel opacification in normal or near-normal epicardial coronary artery (stenosis<40%) when contrast agents are used in coronary angiography.CSF is associated with acute myocardial infarction, ventricular tachycardia, ventricular fibrillation, and even sudden cardiac death.More than 80% of patients experiencing recurrent chest pain, leading to a serious decline in the quality of life.This article reviewed the possible pathogenesis, clinical features, prognostic factors, and therapeutic progress of CSF.

Key words: Coronary slow flow, Coronary angiography, Chest pain

中图分类号:

R543.3

曹梦珠, 乔增勇. 冠状动脉慢血流现象的研究进展[J]. 外科研究与新技术, 2019, 8(1): 44-48.

CAO Mengzhu, QIAO Zengyong. Advances in coronary slow flow[J]. Surgical Research and New Technique, 2019, 8(1): 44-48.

参考文献

[1] Beltrame J F.Defining the coronary slow flow phenomenon[J].Circ J, 2012,76(4):818-820.
[2] Tambe AA, Demany MA, Zimmerman HA, et al.Angina pectoris and slow flow velocity of dye in coronary arteries-a new angiographic finding[J].Am Heart J, 1972,84(1):66-71.
[3] Altunkas F, Koc F, Ceyhan K, et al.The effect of slow coronary flow on right and left ventricular performance[J].Med Princ Pract, 2014,23(1):34-39.
[4] Damaske A, Muxel S, Fasola F, et al.Peripheral hemorheological and vascular correlates of coronary blood flow[J].Clin Hemorheol Microcirc, 2011,49(1-4):261-269.
[5] He W, Huang Y, Zhang Y, et al.Cardiac rehabilitation therapy for coronary slow flow phenomenon[J].Herz, 2018(Epub ahead of print).
[6] Mukhopadhyay S, Kumar M, Yusuf J, et al.Risk factors and angiographic profile of coronary slow flow(CSF) phenomenon in North Indian population:An observational study[J].Indian Heart J, 2018,70(3):405-409.
[7] Harth JE, Ferrari MJ, Helms AM, et al.Corrigendum:zucchini yellow mosaic virus infection limits establishment and severity of powdery mildew in wild populations of Cucurbita pepo[J].Front Plant Sci, 2018,9(4):1815.
[8] Signori LU, Quadros AS, Sbruzzi G, et al.Endothelial function in patients with slow coronary flow and normal coronary angiography[J].Clinics(Sao Paulo), 2012,67(6):677-680.
[9] Chen Z, Chen X, Li S, et al.Nicorandil improves myocardial function by regulating plasma nitric oxide and endothelin-1 in coronary slow flow[J].Coron Artery Dis, 2015,26(2):114-120.
[10] Zhao Z W, Ren YG, Liu J.Low serum adropin levels are associated with coronary slow flow phenomenon[J].Acta Cardiol Sin, 2018,34(4):307-312.
[11] Chen Z, Chen X, Li S, et al.Nicorandil improves myocardial function by regulating plasma nitric oxide and endothelin-1 in coronary slow flow[J].Coron Artery Dis, 2015,26(2):114-120.
[12] Yucel H, Ozaydin M, Dogan A, et al.Plasma concentrations of asymmetric dimethylarginine,nitric oxide and homocysteine in patients with slow coronary flow[J].Scand J Clin Lab Invest, 2012,72(6):495-500.
[13] Amano H, Wagatsuma K, Yamazaki J, et al.Virtual histology intravascular ultrasound analysis of attenuated plaque and ulcerated plaque detected by gray scale intravascular ultrasound and the relation between the plaque composition and slow flow/no reflow phenomenon during percutaneous coronary intervention[J].J Interv Cardiol, 2013,26(3):295-301.
[14] Cin VG, Pekdemir H, Camsar A, et al.Diffuse intimal thickening of coronary arteries in slow coronary flow[J].Jpn Heart J, 2003,44(6):907-919.
[15] Wang Y, Liu MJ, Yang HM, et al.Association between increased serum alkaline phosphatase and the coronary slow flow phenomenon[J].BMC Cardiovasc Disord,2018,18(1):138.
[16] Satiroglu O, Durakoglugil ME, Cetin M, et al.The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow[J].Interv Med Appl Sci, 2016,8(4):158-163.
[17] Emrah A, Akin II, Servet I, et al.Increased circulating soluble urokinase-type plasminogen activator receptor(suPAR) levels in patients with slow coronary flow[J].Arch Med Sci Atheroscler Dis, 2016,1(1):e53-e59.
[18] Turhan H, Saydam GS, Erbay AR, et al.Increased plasma soluble adhesion molecules;ICAM-1, VCAM-1,and E-selectin levels in patients with slow coronary flow[J].Int J Cardiol, 2006,108(2):224-230.
[19] Ozyurtlu F, Yavuz V, Cetin N, et al.The association between coronary slow flow and platelet distribution width among patients with stable angina pectoris[J].Postepy Kardiol Interwencyjnej, 2014,10(3):161-165.
[20] Dogan M, Akyel A, Cimen T, et al.Relationship between neutrophil to lymphocyte ratio and slow coronary flow[J].Clin Appl Thromb Hemost, 2015,21(3):251-254.
[21] Altas Y, Kurtoglu E, Yaylak B, et al.The relationship between eosinophilia and slow coronary flow[J].Ther Clin Risk Manag, 2015,11:1187-1191.
[22] Yurtdas M, Yaylali YT, Kaya Y, et al.Increased plasma high-sensitivity C-reactive protein and myeloperoxidase levels may predict ischemia during myocardial perfusion imaging in slow coronary flow[J].Arch Med Res, 2014,45(1):63-69.
[23] Liu C L, Xue ZQ, Gao SP, et al.The relationship between interleukin-6 promotor polymorphisms and slow coronary flow phenomenon[J].Clin Lab, 2016,62(5):947-953.
[24] Durakoglugil ME, Kocaman SA, Cetin M, et al.Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon:an observational study[J].Anadolu Kardiyol Derg, 2013,13(1):39-44.
[25] Coker A, Arman A, Soylu O, et al.Lack of association between IL-1 and IL-6 gene polymorphisms and myocardial infarction in Turkish population[J].Int J Immunogenet, 2011,38(3):201-208.
[26] Mutluer FO, Ural D, Gungor B, et al.Association of interleukin-1 gene cluster polymorphisms with coronary slow flow phenomenon[J].Anatol J Cardiol, 2018,19(1):34-41.
[27] Kopetz VA, Penno MA, Hoffmann P, et al.Potential mechanisms of the acute coronary syndrome presentation in patients with the coronary slow flow phenomenon - insight from a plasma proteomic approach[J].Int J Cardiol, 2012,156(1):84-91.
[28] Kopetz V, Kennedy J, Heresztyn T, et al.Endothelial function,oxidative stress and inflammatory studies in chronic coronary slow flow phenomenon patients[J].Cardiology, 2012,121(3):197-203.
[29] Kantarci M, Gundogdu F, Doganay S, et al.Arterial bending angle and wall morphology correlate with slow coronary flow:determination with multidetector CT coronary angiography[J].Eur J Radiol, 2011,77(1):111-117.
[30] Yuksel S, Pancar YE, Yenercag M, et al.Abnormal nail fold capillaroscopic findings in patients with coronary slow flow phenomenon[J].Int J Clin Exp Med,2014,7(4):1052-1058.
[31] Masoumi M, Mohammadi K.Coronary slow flow phenomenon and atrioventricular block:A case report[J].J Tehran Heart Cent, 2017,12(2):85-87.
[32] Taha NM, Asklany HT, Mahmoud AH, et al.Retinal fluorescein angiography:A sensitive and specific tool to predict coronary slow flow[J].Egypt Heart J, 2018,70(3):167-171.
[33] Sanati H, Kiani R, Shakerian F, et al.Coronary slow flow phenomenon clinical findings and predictors[J].Res Cardiovasc Med, 2016,5(1):e30296.
[34] Xu Y, Meng HL, Su YM, et al.Serum YKL-40 is increased in patients with slow coronary flow[J].Coron Artery Dis, 2015,26(2):121-125.
[35] Alvarez C, Siu H.Coronary slow-flow phenomenon as an underrecognized and treatable source of chest pain:Case series and literature review[J].J Investig Med High Impact Case Rep, 2018,6(3):23-24.
[36] Beltrame JF, Turner SP, Leslie SL, et al.The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon[J].J Am Coll Cardiol, 2004,44(1):57-62.
[37] Li L, Gu Y, Liu T, et al.A randomized, single-center double-blinded trial on the effects of diltiazem sustained-release capsules in patients with coronary slow flow phenomenon at 6—month follow-up[J].PLoS One, 2012,7(6):e38851.
[38] Baykan AO, Kalkan GY, Sahin DY, et al.Coronary flow velocity reserve in donor artery and myocardial performance index after successful recanalization of chronic total coronary occlusions[J].J Invasive Cardiol, 2015,27(6):E75-E81.
[39] Niu H, Wei Z, Zhang Y, et al.Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow[J].Exp Ther Med, 2018,15(1):904-908.
[40] Wang S H, Chu L, Xu Z, et al.Effect of Shexiang Tongxin Dropping Pills on the immediate blood flow of patients with coronary slow flow[J/OL].Chin J Integr Med,2018[2018-06-18].https://doi.org/10.1007/s11655-018-2559-4# citeas.
[41] Luo C, Liu D, Wu G, et al.Effect of enhanced external counterpulsation on coronary slow flow and its relation with endothelial function and inflammation:a mid-term follow-up study[J].Cardiology, 2012,122(4):260-268.
[42] 曹野,邹远林,王伟琼,等.冠状动脉内微导管给药治疗无复流现象疗效的Meta分析[J].中国介入心脏病学杂志, 2018,26(3):159-166.

冠状动脉慢血流现象的研究进展

Advances in coronary slow flow

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价